Prostate Cancer Features Archive
Knowing that food increases the absorption of some therapies presents the possibility of easily — and significantly — lowering treatment costs.
Results from the Prostate Cancer Prevention Trial indicate that the reduced risk for prostate cancer among men assigned to finasteride continued throughout 16 years of follow-up.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
African Americans have a 60% higher incidence of prostate cancer and are about 2 times more likely to die from the disease.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
A study could not determine whether one liquid biopsy panel is more accurate than another overall.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
New diagnostic and therapeutic tools are in development to inform the management of advanced and metastatic disease.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Hypofractionated radiotherapy's role in postoperative settings remains unclear and awaits outcomes from ongoing studies.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
Up to 20% of patients with prostate cancer treated with radiation therapy — external or internal via brachytherapy — will develop radiation colitis.
More evidence may be needed to understand the safety and efficacy of radium-223 in combination with abiraterone or enzalutamide.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Socioeconomic status, including education and income level, appears to be tied to prostate-specific antigen test results and prostate cancer treatment and survival, but the exact nature of these associations is not yet clear.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
Cancer Therapy Advisor asked Dr David Graham and Dr Alexander Kutikov about the state of the science of circulating tumor cell testing in prostate cancer, as well as this emerging field's potential clinical applications.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
Increased insurance and clinical trial access, plus diversification of the medical workforce, may help to close treatment gaps.
The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
Active surveillance provides an important alternative to immediate treatment for early-stage, low-risk prostate cancers. For men with a relatively short life expectancy, watchful waiting is recommended.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.
If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?
More studies are needed to define the role of intratumoral androgen production and mCRPC resistance to hormonal therapies, and to determine if inhibitors of other steroidogenesis enzymes can be synergistic with abiraterone.
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
A recent study suggests that a liquid biopsy may help oncologists to determine which patients with prostate cancer are likely to respond to enzalutamide or abiraterone.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Two recent studies provide men diagnosed with localized prostate cancer with important information about the adverse events of treatment choices.
According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.
Can liquid biopsy and molecular imaging biomarkers help inform more precise management of patients with metastatic prostate cancer?
Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.
Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.
Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.
Physicians will speak about tumor evolution and AR-indifferent disease at the 2017 ASCO Genitourinary Cancers Symposium in Orlando, Florida.
Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.
PSA nadir greater than 0.5 ng/mL may serve as a surrogate marker to identify men with localized prostate cancer at high risk of mortality.
Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.
Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.
Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.
According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.
The pioneer transcription factor GATA2 has been implicated in prostate tumorigenesis, tumor aggressiveness, treatment resistance, and metastasis, making it a promising biomarker.
Dr Barbara Burtness of Yale University's School of Medicine discusses the relationship between happiness and clinical practice in oncology.
A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.
Differences between the sexes are known in a variety of cancers, but the reasons remain unclear.
CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.
Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.
Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising drug prices.
Short, noncoding regulatory stretches of RNA known as microRNA hold promise as prostate cancer biomarkers.
Researchers are trying to develop prostate cancer biomarkers that can predict treatment effects, to spare patients toxicities associated with unhelpful regimens.
Guidelines and technology are changing, but as the number of clinical trials increases, ensuring that trials are reported will be an increasingly difficult task.
Proponents of competing evolutionary theories seek to explain—and combat—oncogenesis.
Financial hardship is common among cancer survivors in the US, and can be a psychologically and economically debilitating burden.
This inexpensive, web-based treatment may help patients overcome cognitive issues from chemotherapy.
Educating the public about risk factors and prevention strategies remains a major challenge to cancer prevention.
Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.
Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhibiting carcinogenesis.
Prostate-specific antigen screening is not meaningfully less frequent than before guidelines were issued against use of the test.
At War on Cancer, numerous figures in cancer care discussed innovations to reduce the costs associated with drugs.
After a litany of failures for immunotherapies against prostate cancer, calls are mounting for approaches that combine these agents with other treatments.
Contrary to some news headlines, monitoring prostate cancer has different survival implications than treatment after 10 years.
In this Q&A, CTA asked Dr Pal about the ongoing controversy, evidence base, and pivotal studies of intermittent versus continuous androgen deprivation therapy for prostate cancer.
Speakers at the 2016 Concordia Summit's panel, "Precision Medicine in Cancer Research," discussed the importance and future of immunotherapy for cancer treatment.
In this question-and-answer session, CTA asked Dr Carroll about CRISPR-Cas9, the state of the science of genome editing, and its implications for oncology.
CRISPR is receiving attention as a gene-editing tool that may help us treat cancer, but evolutionary theory suggests a much more complex reality.
Overselling scientific data contributes to misunderstanding, failure, and disappointment in real-world settings.
Patients who slept poorly exhibited greater symptom burden and overall mood disturbance.
The federal government is investigating some drugmakers' relationships with the charities that run assistance programs.
Widespread contamination of the Prostate, Lung, Colorectal, and Ovary (PLCO) Cancer Screening Trial has reignited the debate around prostate-specific antigen testing.
Quantifications of quality of life or patient-reported outcomes will offer more information for treatment-planning discussions.
Sexual function scores do not appear to differ between the 2 groups at 6 weeks or 12 weeks post-surgery, and no significant differences were found for bowel quality of life or pathological outcomes.
Humans can tolerate tumors in large or paired organs more easily than in small, critical organs, and the larger organs may therefore have evolved fewer mechanisms to defend against cancerous cells.
Q&A With Emmanuel Antonarakis, MD: AR-V7 "Liquid Biopsy" Can Avoid Unneeded Treatment, Curb Health Care Costs
AR-V7 has been implicated in metastatic prostate tumor resistance to the androgen-receptor signaling (ARS) blockers abiraterone and enzalutamide.
As our aging workforce expands, a decreasing number of young investigators are applying for National Institute of Health (NIH) R01-equivalent grants.
New biomarkers might revolutionize prostate cancer treatment, according to an educational presentation at the 2016 ASCO Annual Meeting in Chicago.
Men with P. acnes found in their prostate tissue biopsy are more than 4 times as likely to develop prostate cancer as others.
Instead of analyzing adverse events (AEs) in the traditional fashion, we ought to consider alternatives in this new era of personalized medicine.
Using a new methodology called a "neighborhood-wide association study," researchers have identified 17 variables, out of more than 14,600, that were significantly associated with prostate cancer aggressiveness.
The senescence-associated secretory phenotype can promote tumorigenesis under certain conditions, and may offer a target for senolytic therapy.
ASCO states that it supports Congress, the Obama Administration, and multiple federal agencies in their efforts to prevent and respond to prescription drug abuse.
Preventing Overtreatment of Prostate Cancer: New Model Identifies Ideal Patients for Active Surveillance
A new care model for patients with low-risk prostate cancer may help prevent disease overtreatment.
Investigators found that cell-free DNA is released into circulation by cancer cells undergoing apoptosis or necroptosis in the primary or metastatic cancer lesions.
How will breakthroughs in vaccine-based immunotherapies and the National Cancer Moonshot Initiative impact clinical practice?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC
- Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma
- Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia
- Can Oncolytic Viruses Improve Immunotherapies?
- Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia
- Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL
- Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations
- Can Oncolytic Viruses Improve Immunotherapies?
- Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors
- CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer